Grace Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Jun 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 18, 2026
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Loss and Comprehensive Loss
Comprehensive Loss
| Year Ended March 31, 2026 | Year Ended March 31, 2025 | |
|---|---|---|
| (Expressed in thousands, except share and per share data) | $ | $ |
| Operating expenses | ||
| Research and development expenses | 2,405 | 9,511 |
| General and administrative expenses | 8,672 | 7,168 |
| Loss from operating activities | (11,077) | (16,679) |
| Foreign exchange loss | (1) | (17) |
| Change in fair value of derivative warrant liabilities | 900 | 3,218 |
| Interest and other income, net | 685 | 711 |
| Total other income, net | 1,584 | 3,912 |
| Loss before income tax benefit | (9,493) | (12,767) |
| Income tax benefit | 1,700 | 3,199 |
| Net loss and total comprehensive loss | (7,793) | (9,568) |
| Basic and diluted loss per share | (0.47) | (0.79) |
| Weighted-average number of shares outstanding | 16,510,632 | 12,087,270 |
Consolidated Statements of
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.